Novocure

At Novocure, leadership development means more than building skills — it’s about deepening our connection to our mission: extending survival in some of the most aggressive forms of cancer. Through NovoAcademy, we empower leaders at all levels to grow with purpose. This year, two of our flagship programs brought together leaders from around the world: The Advanced Leadership Program took place in June at the University of St.Gallen (HSG) – Executive School in Switzerland. Earlier this year, 32 colleagues completed the Enterprise Leadership Program, culminating in a capstone week at Harvard Business School Executive Education, tackling real-world Novocure business challenges. Congratulations to all alumni - and thank you for your commitment to leading with impact. #NovoAcademy #LeadershipDevelopment #ExecutiveEducation #GlobalLeadership #PatientForward

Novocure today reported financial results for the second quarter ended June 30, 2025. Read the press release: https://lnkd.in/dKJGN_Vf

Novocure today reported financial results for the second quarter ended June 30, 2025. Read the press release: https://lnkd.in/dKJGN_Vf

Congratulations to the 23 Novocure runners from our team in Germany for successfully completing the “B2Run 2025” race in Munich! And a big thank you to all the colleagues who cheered for them along the 5.7km (3.5 mile) route. This event was a great opportunity to spend time with colleagues outside of the office. #WeAreNovocure #B2RunMunich To learn more about Novocure or join our team, visit our careers page: https://lnkd.in/eVZKr7r

Today is Glioblastoma Awareness Day. At Novocure, we are committed to advancing the treatment and research of #glioblastoma, one of the most aggressive forms of brain cancer. We are proud to support the National Brain Tumor Society for their leadership of the #GBMAwarenessDay initiative. #GBMDay #BTAM #GBMAwarenessDay

#PancreaticCancer Update from the ESMO Gastrointestinal (GI) Cancers Congress 2025: The final secondary endpoint results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer were presented today as an oral presentation at ESMO GI. Learn more in our press release: https://lnkd.in/d_JnZpen

Novocure will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025. Read more in our press release: https://lnkd.in/d_JnZpen #ESMOGI25 #PancreaticCancer

Novocure will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Read more in our press release: https://lnkd.in/dJ-BMpbB

Many cancers can spread from their original site into other regions of the human body. These relocated cancer deposits called metastases can affect important parts of the body’s nervous system such as the brain and cerebrospinal fluid. Lung cancer is the leading source of brain metastasis in men, and breast cancer is the leading source for brain metastasis in women.   June is Brain and Spine Metastasis Awareness Month. We are proud to support the Metastatic Brain Tumor Collaborative, created by the American Brain Tumor Association to inform, support and empower people facing this diagnosis. Learn more about metastatic brain tumors here: https://lnkd.in/gdsy7mki   #BrainMetastases #MetastaticBrainCancer #MetsGetAwareness

Results from the 2-THE-TOP trial led by David D. Tran, MD, PhD, Chief, Division of Neuro-Oncology, Department of Neurosurgery, Co-Director, University of Southern California (USC) Brain Tumor Center Keck Medicine of USC, were published by the Cell Press journal, 𝘔𝘦𝘥. The 2-THE-TOP trial, “The publication, Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma (2-THE-TOP): A Phase 2 study,” assessed the efficacy and safety of TTFields therapy when used with pembrolizumab and temozolomide to treat newly diagnosed glioblastoma (GBM). This publication provides additional characterization of the immunogenic effects observed with TTFields therapy. https://lnkd.in/edSQNpsu